摘要
目的:研究长效干扰素人血清白蛋白融合干扰素(HSA-IFNα2b)对HepG2.2.15细胞增殖、凋亡及其HBsAg与HBeAg表达的影响,探讨其体外抑制乙肝病毒的机制。方法:采用SRB法分析HSA-IFNα2b作用HepG2.2.15细胞3,6 d后对其增殖的影响,酶联免疫分析不同剂量HSA-IFNα2b作用不同时间后HepG2.2.15细胞HBsAg与HBeAg的表达水平,Hochest33342、PI双染法观察细胞的凋亡和死亡,Western Blot印迹检测Bcl-2、Bax的表达。结果:HepG2.2.15细胞的增殖在加HSA-IFNα2b作用3,6 d后都有所抑制,细胞培养上清中HBsAg表达明显下降,并与浓度相关,HSA-IFNα2b浓度为10 000 U.mL-1时,培养6 d后HBsAg的抑制率达87%以上。Hochest33342、PI双染结果显示当HSA-IFNα2b浓度在1 250U.mL-1时可见少量的凋亡细胞,凋亡细胞数随着药物浓度的增大而增多,并有少量死亡细胞出现。Western Blot印迹检测随药物浓度的增加Bcl-2的表达降低而Bax的表达增加。结论:HSA-IFNα2b体外可明显抑制HepG2.2.15细胞的增殖及HB-sAg的表达,并可引起HepG2.2.15细胞的凋亡和死亡。
OBJECTIVE To evaluate the effects of a long-acting interferon (HSA-IFNa2b) on the proliferation, apoptosis and expression of HBsAg and HBeAg in HepG 2.2. 15 cells, and to investigate the mechanism of inhibition of hepatitis B virus in vitro. METHODS The cells proliferation was determined by SRB method. The expression levels of HBsAg and HBeAg in supernatant were measured using enzyme-linked dimmunosorbent assay (ELISA). Apoptosis and death were observed by Hochest33342 and PI double staining. Expression of Bcl-2 and Bax proteins were determined with Western blot. RESULTS The results demonstrated that HSA-IFNa2b could inhibit the proliferation of HepG 2. 2. 15 cells. The expression of HBsAg in HepG 2. 2.15 cells was inhibited by HSA-IFNa2b in a time and dose-dependent manner. Treated with 10 000 u.mL^-1 HSAIFNa2b for six days, the inhibitiory rates of HBsAg was above 87%. The Results of Hochest33342 and PI double staining demonstrated HSA-IFNa2b could induce the apoptosis of HepG 2. 2. 15 cells in a dose-dependent manner. The cell death was also occurred at the higher concentration of HSA-IFNa2b. The results of Western blot analysis showed that HSA-IFNa2b could inhibit the expression of Bcl-2, while enhance the expression of Bax. CONCLUSION HSA-IFNa2b could not only significantly inhibit the HBsAg expression and the proliferation of HepG 2. 2. 15 cells, but also induced the apoptosis and death.
出处
《中国医院药学杂志》
CAS
CSCD
北大核心
2012年第2期100-103,共4页
Chinese Journal of Hospital Pharmacy
基金
国家自然科学基金(编号:30670589)
卫生部科研基金(编号:wkj2006-2-5)
江苏省医学重点人才项目(编号:RC2007097)
江苏省人事厅“六大人才高峰”(编号:06-B-026)